Anavex Life Sciences Corp.AVXLNASDAQ
Loading
Year-over-year operating cash flow growth rate
Latest
16.89%
↑ 183% vs avg
Percentile
P64
Within normal range
Streak
1 qtr
Consecutive declineDecelerating
Average
-20.23%
Historical baseline
| Period | Value |
|---|---|
| Q4 2025 | 16.89% |
| Q3 2025 | 30.97% |
| Q2 2025 | -112.84% |
| Q1 2025 | 51.68% |
| Q4 2024 | -82.04% |
| Q3 2024 | -28.53% |
| Q2 2024 | 55.56% |
| Q1 2024 | -59.28% |
| Q4 2023 | -25.10% |
| Q3 2023 | 23.56% |
| Q2 2023 | 9.85% |
| Q1 2023 | -46.51% |
| Q4 2022 | -43.28% |
| Q3 2022 | 42.67% |
| Q2 2022 | 26.83% |
| Q1 2022 | -175.34% |
| Q4 2021 | 54.38% |
| Q3 2021 | -2.04% |
| Q2 2021 | -2.79% |
| Q1 2021 | 7.04% |
| Q4 2020 | -25.85% |
| Q3 2020 | -54.66% |
| Q2 2020 | 23.16% |
| Q1 2020 | 8.07% |
| Q4 2019 | -125.91% |
| Q3 2019 | 66.21% |
| Q2 2019 | -73.18% |
| Q1 2019 | -4.12% |
| Q4 2018 | -2.64% |
| Q3 2018 | -94.10% |
| Q2 2018 | 25.98% |
| Q1 2018 | 22.08% |
| Q4 2017 | -65.16% |
| Q3 2017 | 26.30% |
| Q2 2017 | -326.23% |
| Q1 2017 | 77.87% |
| Q4 2016 | -69.25% |
| Q3 2016 | 16.21% |
| Q2 2016 | -16.89% |
| Q1 2016 | 41.41% |